Impairment in Immunomodulatory Function of Mesenchymal Stem Cells from Multiple Myeloma Patients

Archives of Medical Research

Volumn 41, Issue 8, 2010, Pages 623-633

  Li, Bingzong ^a   Fu, Jinxing ^a   Chen, Ping ^a   Zhuang, Wenzhuo ^b  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

Immunomodulatory; Mesenchymal stem cells; Multiple myeloma; Osteogenesis; T cells

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BETA1 INTEGRIN; CD133 ANTIGEN; CD34 ANTIGEN; CD44V ANTIGEN; CD45 ANTIGEN; ENDOGLIN; FAS LIGAND; HLA DR ANTIGEN; INTERLEUKIN 3; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE DEVELOPMENT; CD3+ T LYMPHOCYTE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL FUNCTION; CELL STRUCTURE; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; MESENCHYMAL STEM CELL; MULTIPLE MYELOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AGED; ANIMALS; ANTIGENS, CD; APOPTOSIS; CELLS, CULTURED; CYTOKINES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTE ACTIVATION; MALE; MESENCHYMAL STEM CELLS; MIDDLE AGED; MULTIPLE MYELOMA; T-LYMPHOCYTES;

EID: 78650749445     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2010.11.008     Document Type: Article

References (38)

1. Berenson J., Wong R., Kim K., et al. Evidence for peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma. Blood 1987, 70:1550-1553.
2. Massaia M., Bianchi A., Attisano C., et al. Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex. Blood 1991, 78:1770-1780.
3. Shapira R., Froom P., Kinarty A., et al. Increase in the suppressor-inducer T cell subset in multiple myeloma and monoclonal gammopathy of undetermined significance. Br J Haematol 1989, 71:223-225.
4. Prabhala R.H., Neri P., Bae J.E., et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006, 107:301-304.
5. Dominici M., Le Blanc K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
6. Fibbe W.E., Nauta A.J., Roelofs H. Modulation of immune responses by mesenchymal stem cells. Ann NY Acad Sci 2007, 1106:272-278.
7. Yoo K.H., Jang I.K., Lee M.W., et al. Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol 2009, 259:150-156.
8. Li B., Shi M., Li J., et al. Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma. Stem Cells Dev 2007, 16:921-930.
9. Barille-Nion S., Bataille R. New insights in myeloma-induced osteolysis. Leuk Lymphoma 2003, 44:1463-1467.
10. Bataille R., Chappard D., Marcelli C., et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 1989, 7:1909-1914.
11. Giuliani N., Colla S., Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol 2004, 32:685-691.
12. Gregory C.A., Gunn W.G., Reyes E., et al. How Wnt signaling affects bone repair by mesenchymal stem cells from the bone marrow. Ann NY Acad Sci 2005, 1049:97-106.
13. Giuliani N., Colla S., Morandi F., et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005, 106:2472-2483.
14. Tian E., Zhan F., Walker R., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483-2494.
15. Gonzalo-Daganzo R., Regidor C., Martin-Donaire T., et al. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults. Cytotherapy 2009, 11:278-288.
16. Wolff D., Steiner B., Hildebrandt G., et al. Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease. Curr Pharm Des 2009, 15:1974-1997.
17. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
18. Joshua D.E., Brown R.D., Ho P.J., et al. Regulatory T cells and multiple myeloma. Clin Lymphoma Myeloma 2008, 8:283-286.
19. Glennie S., Soeiro I., Dyson P.J., et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005, 105:2821-2827.
20. Le Blanc K., Rasmusson I., Gotherstrom C., et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol 2004, 60:307-315.
21. Plumas J., Chaperot L., Richard M.J., et al. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 2005, 19:1597-1604.
22. Opitz C.A., Litzenburger U.M., Lutz C., et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem cells 2009, 27:909-919.
23. Xue Q., Luan X.Y., Gu Y.Z., et al. The negative co-signaling molecule b7-h4 is expressed by human bone marrow-derived mesenchymal stem cells and mediates its T-cell modulatory activity. Stem Cells Dev 2010, 19:27-38.
24. Yang S.H., Park M.J., Yoon I.H., et al. Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med 2009, 41:315-324.
25. Chen K., Wang D., Du W.T., et al. Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism. Clin Immunol 2010, 135:448-458.
26. Arnulf B., Lecourt S., Soulier J., et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 2007, 21:158-163.
27. Anderson D.M., Maraskovsky E., Billingsley W.L., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175-179.
28. Giuliani N., Colla S., Morandi F., et al. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment. Haematologica 2004, 89:1118-1123.
29. Tanaka S., Nakamura K., Takahasi N., et al. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 2005, 208:30-49.
30. Giuliani N., Morandi F., Tagliaferri S., et al. Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients. Blood 2006, 107:841-842.
31. Kawamoto K., Pahuja A., Hering B.J., et al. Transforming growth factor beta 1 (TGF-beta1) and rapamycin synergize to effectively suppress human T cell responses via upregulation of FoxP3+ Tregs. Transpl Immunol 2010, 23:28-33.
32. Di Nicola M., Carlo-Stella C., Magni M., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
33. Colucci S., Brunetti G., Rizzi R., et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 2004, 104:3722-3730.
34. Ehrlich L.A., Chung H.Y., Ghobrial I., et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 2005, 106:1407-1414.
35. Weitzmann M.N., Cenci S., Rifas L., et al. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood 2000, 96:1873-1878.
36. Liu Y.L., Jiang X.X., Su Y.F., et al. Activated T cells promote differentiation of mesenchymal stem cells into osteoblasts. Zhongguo shi yan xue ye xue za zhi 2009, 17:974-976.
37. Bataille R., Chappard D., Marcelli C., et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 1991, 88:62-66.
38. Bataille R., Delmas P.D., Chappard D., et al. Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications. Cancer 1990, 66:167-172.